Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Other: PSP
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Biogen
- Target Recruit Count
- 353
- Registration Number
- NCT04221191
- Locations
- 🇫🇷
Pole de Sante Du Plateau, Clamart, France
🇫🇷Cabinet du Dr Pierre Gras, Dijon, France
🇫🇷Cabinet médical Montebello, Lille, France
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 31
- Registration Number
- NCT04145440
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Northwest Louisiana Nephrology Research, Shreveport, Louisiana, United States
🇳🇱Radboud UMC Niimegen Nephrology, Nijmegen, Netherlands
Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 6
- Registration Number
- NCT04145284
- Locations
- 🇩🇪
Research Site, Dresden, Saxony, Germany
Scan-Rescan Sub-Study of MS PATHS
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT04123353
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
- Conditions
- Healthy VolunteersDiabetic Neuropathies
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Biogen
- Registration Number
- NCT04106050
Angelman Syndrome (AS) Biomarker Study
- Conditions
- Chromosome 15q Duplication (dup15q) SyndromeAngelman Syndrome
- Interventions
- Procedure: Lumbar PunctureProcedure: Blood Collection
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT04103333
- Locations
- 🇺🇸
Rush Medical College, Chicago, Illinois, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸University of North Carolina Hospital, Carolina, North Carolina, United States
A Real-world Study of Imraldi® Use
- Conditions
- Arthritis, Rheumatoid (RA)Axial Spondyloarthritis (axSpA)Arthritis, Psoriatic (PsA)Crohn's Disease (CD)Colitis, Ulcerative (UC)
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1000
- Registration Number
- NCT04089514
- Locations
- 🇬🇧
Research Site, Sussex, United Kingdom
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 145
- Registration Number
- NCT04089566
- Locations
- 🇯🇵
Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo-To, Japan
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇷🇺Regional Pediatric Clinical Hospital #1, Ekaterinburg, Russian Federation
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Biogen
- Registration Number
- NCT04079088
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 31
- Registration Number
- NCT04079101
- Locations
- 🇺🇸
Research Site, Long Beach, California, United States